Christopher D. Payne
Eli Lilly (United States)(US)
Publications by Year
Research Areas
Antiplatelet Therapy and Cardiovascular Diseases, Lipoproteins and Cardiovascular Health, Inflammatory mediators and NSAID effects, Atrial Fibrillation Management and Outcomes, Venous Thromboembolism Diagnosis and Management
Most-Cited Works
- → Common polymorphisms of CYP2C19 and CYP2C9 affect the pharmacokinetic and pharmacodynamic response to clopidogrel but not prasugrel(2007)727 cited
- → A comparison of prasugrel and clopidogrel loading doses on platelet function: magnitude of platelet inhibition is related to active metabolite formation(2006)568 cited
- → Prasugrel achieves greater inhibition of platelet aggregation and a lower rate of non-responders compared with clopidogrel in aspirin-treated patients with stable coronary artery disease(2006)536 cited
- → Cytochrome P450 3A Inhibition by Ketoconazole Affects Prasugrel and Clopidogrel Pharmacokinetics and Pharmacodynamics Differently(2007)321 cited
- → Effects of the Proton Pump Inhibitor Lansoprazole on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel(2008)315 cited
- → Tadalafil pharmacokinetics in healthy subjects(2005)282 cited
- → Increased Active Metabolite Formation Explains the Greater Platelet Inhibition With Prasugrel Compared to High-dose Clopidogrel(2007)167 cited
- → The use of the VerifyNow P2Y12 point-of-care device to monitor platelet function across a range of P2Y12 inhibition levels following prasugrel and clopidogrel administration(2008)120 cited
- → The Platelet Inhibitory Effects and Pharmacokinetics of Prasugrel After Administration of Loading and Maintenance Doses in Healthy Subjects(2006)89 cited
- → Effect of Atorvastatin on the Pharmacokinetics and Pharmacodynamics of Prasugrel and Clopidogrel in Healthy Subjects(2008)87 cited